Hongbin Tang, Yong Liu, Yabing Yu, Jun Zhou, Jiaomei Yang
{"title":"The predictive value of CK-MB on the curative effect of urokinase combined with LMWH calcium in AMI.","authors":"Hongbin Tang, Yong Liu, Yabing Yu, Jun Zhou, Jiaomei Yang","doi":"10.1080/17520363.2024.2429367","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study investigates the predictive value of CK-MB in treating acute myocardial infarction (AMI) with urokinase combined with low molecular weight heparin (LMWH) calcium.</p><p><strong>Methods: </strong>AMI patients treated at our hospital from April 2020 to August 2022 were included in this prospective, multi-center cohort study. Patients were randomly assigned to a urokinase group or a combined treatment group (urokinase plus LMWH). CK-MB levels were measured using ELISA, and adverse reactions were recorded. The accuracy of CK-MB as a predictor was evaluated via ROC curve analysis and AUC.</p><p><strong>Results: </strong>Before treatment, CK-MB levels were similar in both groups (<i>p</i> > 0.05). Post-treatment, levels were significantly lower in the combined group (<i>p</i> < 0.05). The combined group had a higher proportion of mild CK-MB elevation and lower moderate/severe elevations (<i>p</i> < 0.05). Adverse reaction rates were similar (<i>p</i> > 0.05). The combined treatment group showed higher effectiveness (<i>p</i> < 0.05), with better sensitivity (94%) and specificity (82%) than the urokinase group (sensitivity 89%, specificity 78%).</p><p><strong>Conclusion: </strong>CK-MB is a valuable predictor for evaluating the efficacy of urokinase plus LMWH in AMI treatment, offering advantages in reducing CK-MB levels and improving outcomes.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1087-1092"},"PeriodicalIF":1.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654802/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2024.2429367","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study investigates the predictive value of CK-MB in treating acute myocardial infarction (AMI) with urokinase combined with low molecular weight heparin (LMWH) calcium.
Methods: AMI patients treated at our hospital from April 2020 to August 2022 were included in this prospective, multi-center cohort study. Patients were randomly assigned to a urokinase group or a combined treatment group (urokinase plus LMWH). CK-MB levels were measured using ELISA, and adverse reactions were recorded. The accuracy of CK-MB as a predictor was evaluated via ROC curve analysis and AUC.
Results: Before treatment, CK-MB levels were similar in both groups (p > 0.05). Post-treatment, levels were significantly lower in the combined group (p < 0.05). The combined group had a higher proportion of mild CK-MB elevation and lower moderate/severe elevations (p < 0.05). Adverse reaction rates were similar (p > 0.05). The combined treatment group showed higher effectiveness (p < 0.05), with better sensitivity (94%) and specificity (82%) than the urokinase group (sensitivity 89%, specificity 78%).
Conclusion: CK-MB is a valuable predictor for evaluating the efficacy of urokinase plus LMWH in AMI treatment, offering advantages in reducing CK-MB levels and improving outcomes.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
